AstraZeneca and Bristol Myers Squibb merger talks denied

"There is nary woody betwixt AstraZeneca and BMS. There ne'er was a woody to beryllium done, and determination are nary discussions betwixt the companies," the root said, nether the screen of anonymity. Neither institution offered a remark erstwhile contacted by Reuters.

The denial came days aft reports that the 2 pharmaceutical companies had been successful preliminary discussions astir a operation that could person created a institution worthy adjacent to $400 billion. The Financial Times archetypal reported the story. Reuters, which broke the Sunday communicative connected the preliminary talks, noted astatine the clip that it could not corroborate whether those conversations were inactive active.

AstraZeneca shares dropped astir 9% successful the aftermath of the woody reports, portion Bristol Myers Squibb shares weathered the quality with comparatively small movement.

When the merger reports archetypal surfaced, arsenic covered earlier this week, AstraZeneca banal tumbled arsenic overmuch arsenic 7% connected Monday. Bristol Myers Squibb banal roseate 6% successful U.S. premarket trading. Analysts astatine Jefferies questioned the strategical rationale, penning that AstraZeneca was a institution that did not request "financial engineering." Citi analysts called the reported talks a "surprise" fixed AstraZeneca's pipeline, according to CNBC.

The 2 companies person important overlap successful oncology, a origin that would person drawn antitrust scrutiny had a woody moved forward. AstraZeneca's oncology franchise generated astir $25 cardinal past year, representing adjacent to fractional of its full revenue. Cancer drugs accounted for much than 40% of Bristol Myers Squibb income done the archetypal six months of 2026. Before Monday's session, AstraZeneca carried a marketplace capitalization of $264 billion, portion Bristol Myers Squibb's stood astatine astir $133 billion.

Bristol Myers Squibb has faced unit arsenic exclusivity periods upwind down connected immoderate of its astir important medicines, including crab immunotherapy Opdivo and humor thinner Eliquis, some of which could look generic contention by 2028. The institution raised its full-year gross forecast past week, driven by Eliquis and newer drugs including bosom attraction Camzyos and anemia cause Reblozyl.